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Background: Foot-and-mouth disease (FMD) is the most economically important and highly contagious disease of
cloven-hoofed animals worldwide. Control of the disease has been mainly based on large-scale vaccinations with
whole-virus inactivated vaccines. In recent years, a series of outbreaks of type O FMD occurred in China (including
Chinese Taipei, Chinese Hong Kong) posed a tremendous threat to Chinese animal husbandry. Its causative agent,
type O FMDV, has evolved into three topotypes (East–South Asia (ME-SA), Southeast Asia (SEA), Cathay (CHY)) in
these regions, which represents an important obstacle to disease control. The available FMD vaccine in China
shows generally good protection against ME-SA and SEA topotype viruses infection, but affords insufficient
protection against some variants of the CHY topotype. Therefore, the choice of a new vaccine strain is of
fundamental importance.
Results: The present study describes the generation of a full-length infectious cDNA clone of FMDV vaccine strain
and a genetically modified virus with some amino acid substitutions in antigenic sites 1, 3, and 4, based on the
established infectious clone. The recombinant viruses had similar growth properties to the wild O/HN/CHA/93 virus.
All swine immunized with inactivated vaccine prepared from the O/HN/CHA/93 were fully protected from
challenge with the viruses of ME-SA and SEA topotypes and partially protected against challenge with the virus of
CHY topotype at 28 days post-immunization. In contrast, the swine inoculated with the genetically modified
vaccine were completely protected from the infection of viruses of the three topotypes.
Conclusions: Some amino acid substitutions in the FMDV vaccine strain genome did not have an effect on the
ability of viral replication in vitro. The vaccine prepared from genetically modified FMDV by reverse genetics
significantly improved the protective efficacy to the variant of the CHY topotype, compared with the wild O/HN/
CHA/93 virus. Thus, the full-length cDNA clone of FMDV can be a useful tool to develop genetically engineered
FMDV vaccine candidates to help control porcinophilic FMD epidemics in China.Background
Foot-and-mouth disease (FMD) is a highly contagious
vesicular disease of domestic and wild cloven-hooved
animal species, which is caused by the foot-and-mouth
disease virus (FMDV), the prototype member of the
genus Aphthovirus of the family Picornaviridae. The
highly contagious nature of FMDV and the associated* Correspondence: liuzaixin3@hotmail.com
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reproduction in any medium, provided the orhigh morbidity and productivity losses make it one of
the most important barriers to the world trade of live
animals and animal products. Control of the disease has
been based on large-scale vaccinations with whole-virus
inactivated vaccines, limitation of animal movements
and destruction of herds exposed to the virus [1,2]. The
currently available vaccine shows generally good protec-
tion against infection with the homologous and anti-
genically related viruses. However, difficulties facing the
eradication of FMD include the antigenic diversity of
FMDV in nature, which has been reflected in the identi-
fication of seven serotypes (A, O, C, SAT1, SAT2, SAT3his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The origin of type O foot-and-mouth disease







O/HN/CHA/93 AJ131468 Porcine HeNan 1993
O/Chu-pei/TAW/97 AF026168 Porcine Taiwan 1997
O/HKN/2002 AY317098 Porcine Hong Kong 2002
O/Tau-Yuan/TAW/97 AF154271 Porcine Taiwan 1997
O/Yun/TAW/97 AF308157 Porcine Taiwan 1997
O/Peng-Hu/TAW/
108/99
AY593833 ? Taiwan 1999
otaiwan97 iso106/112 AY593835 ? Taiwan 1997
O/ES/2001 AY686687 ? ? 2001
O/lz DQ248888 ? ? ?
O/WFL EF175732 ? ? ?
O/HK/2001 EU400597 Porcine Hong Kong 2001
O-TW-257-2009 GQ292739 Porcine Taiwan 2009
O-TW-258-2009 GQ292740 Porcine Taiwan 2009
O/HKN/8/2004 DQ164885 Porcine Hong Kong 2004
O/HKN/11/2004 DQ164888 Porcine Hong Kong 2004
O/HKN/2/2003 DQ164879 Porcine Hong Kong 2003
O/HKN/1/99 AJ294925 Porcine Hong Kong 1999
O-TW-256-2001 GQ292738 Porcine Taiwan 2001
O/PEN/TAW/4/99 AJ294928 Porcine Taiwan 2001
Question mark (?) indicates that data are absent.
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often co-circulate in a given geographical area [4]. The
emergence of antigenically novel viruses, against which
existing vaccines do not provide adequate protection,
may require the selection of new vaccine strains to con-
trol the viruses circulating in the field.
The FMD virion consists of a single-stranded RNA
genome packaged in an icosahedrally symmetric protein
shell, which is composed of 60 copies each of four struc-
tural proteins 1A (VP4), 1B (VP2), 1 C (VP3) and 1D
(VP1) [5]. Three of these proteins, VP1, VP2 and VP3,
contribute to the formation of five known antigenic sites
of type O FMDV [6,7]. The G-H loop and carboxy
terminus of VP1 contribute to site 1, key residues have
been shown to be 144, 148, 154 and 208, respectively.
Amino acids at positions 31, 70–73, 75 and 77 of VP2
contribute to site 2. Site 3 involves the B-C loop of VP1,
in which key residues have been shown to be 43 to 48
[6]. Only one critical residue, at position 58 of VP3, has
been identified for site 4. Site 5 maps to a single residue
(residue 149) on the G-H loop of VP1 that is distinct
from site 1. While much of the antibody response to
FMDV can be directed at the G-H loop of VP1, all of
the sites appear to be necessary for a complete immuno-
logic response to either infection or vaccination [8,9].
Among the seven serotypes of FMDV, serotype O is
prevalent in China (including Chinese Taipei, Chinese
Hong Kong) and its surrounding countries [10-13]. Re-
cent studies have showed that type O FMDV in these
region were clustered into three topotypes, namely Mid-
dle East–South Asia (ME-SA), Southeast Asia (SEA),
and Cathay (CHY) [13,14]. An inactivated FMD vaccine
prepared from O/HN/CHA/93 strain that belongs to
the CHY topotype [15], is currently available in China.
This vaccine is used to protect against type O FMD
epidemics, which often provides complete protection
against ME-SA and SEA topotype virus infection, but
can’t affords good protection against some variants of
the CHY topotype. Therefore, the development of new
vaccine strains is of urgently needed. However, the
development of useful cell-culture-adapted vaccine
strains from field isolates is time-consuming and expen-
sive, limiting the availability of custom-made vaccine
strains [16]. The recent progress in animal RNA virus
vaccine development, particularly the reverse genetics
system-based for vaccine development [17-21], provided a
perspective on potential novel strategies and approaches
to develop a virus vaccine candidate.
The present study describes the generation of an infec-
tious cDNA clone of FMDV O/HN/CHA/93 vaccine
strain and a genetically modified virus with some amino
acid substitutions in antigenic site 1 (VP1 134 C! S, 137
S !G, 139 A!T, 140 R! S, 142 V!T, 142 S!N),
site 3 (VP1 43 T!K, 48 I!V), and site 4 (VP3 58 E!D),based on the established infectious clone. The replication
kinetics in vitro of the recombinant viruses and the pro-
tective efficacy of inactivated oil-emulsified vaccines pre-
pared from the genetically modified virus and the wild
O/HN/CHA/93 virus against isolates of three topotypes
were evaluated.
Methods
Analysis of amino acid variation of isolates of CHY topotype
The P1 or VP1 sequence data of 18 FMD reference isolates
were obtained from GenBank. O/HN/CHA/93 shared high
homology with O/GD/China/86 (GenBank AJ131468) [22].
The deduced amino acid sequence alignments were pre-
pared using the data for each FMDV using SeqMan II
(DNAStar Lasergene 8.0). In brief, the amino acid
sequences of P1 or VP1 were maximally aligned using the
MegAlign program. All the reference isolates were clustered
into the CHY topotype [11,12,23-25]. Table 1 shows the ori-
gin of all reference isolates characterized in the present
study and Figure 1 shows the analysis of amino acid
sequences of vaccine strain and reference strains.
Cell lines, viruses
Baby hamster kidney cell (BHK-21) [26] was main-
tained in Dulbecco’s Modified Eagle Medium (DMEM)
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cells (a BHK derivative that stably expresses T7 RNA
polymerase) [27], were maintained in Glasgow Minimal
Essential Medium (GMEM) supplemented with 4% tryp-
tose phosphate broth, 10% FBS, and in alternate passages
geneticin was added to 1 mg/ml to ensure maintenance
of the T7 polymerase gene.
FMDV O/HN/CHA/93 vaccine strain was used to con-
struct the infectious clone and genetically modified mu-
tant. O/HN/CHA/93 was adapted to grow in BHK cells for
use in preparation of an inactivated vaccine to help control
type O FMD epidemics in China. The O/Tibet/CHA/99,
O/TAW/TL/97, and O/JX/CHA/2010 viruses used in the
present study were obtained from the National FMD Ref-
erence Laboratory at Lanzhou Veterinary Research In-
stitute. The O/Tibet/CHA/99 strain is of the ME-SA
topotype [24], the O/TAW/TL/97 strain is of the CHY
topotype [24], whereas the O/JX/CHA/2010 strain was ori-
ginally isolated in China in 2010 and is of the SEA topo-
type [28]. Three viruses were titrated in BHK-21 cells.
Construction of genome-length cDNA clone of O/HN/
CHA/93 vaccine strain
All the molecular constructs were prepared by using
standard molecular biological techniques [29]. Total
RNAs were extracted from the virus stock of O/HN/
CHA/93 using RNeasy mini kit (Qiagen). Viral cDNAs
were performed using M-MLV reverse transcriptase
(Invitrogen) and specific RT primers. Four overlapping
cDNA fragments (designated Z1-Z4 (Figure 2)), repre-
senting the entire viral RNA genome, were amplified
by PCR using primer sets Z1/Z1′, Z2/Z2′, Z3/Z3′ and
Z4/Z4′, respectively. Table 2 lists the primers used to
perform RT-PCR for preparation of full-length cDNA
clones of O/HN/CHA/93 virus. The Z1 primer contains
a Spe I site, T7 promoter sequence and three nonviral G
residues at the 5′ end of the FMDV genome, the Z4′
primer was engineered to add a Not I site following the
viral poly(A) tail sequence. The PCRs were carried out
using PrimeSTAR HS DNA Polymerase (Takara) to
enhance the fidelity during the DNA synthesis. The Z1
and Z2 fragments were then fused by a second round
of PCR with primers Z1 and Z2′ to generate Z12 frag-
ment. Subsequently, the resulting amplicons was ligated
into the pMD-20 vector, leading to the positive clone
pMDZ12. The other two PCR products (Z3 and Z4)
were separately cloned into the corresponding site of M-
pSK vector [30], which is a derivative of pBluescriptSK
(+) vector by removing T7 promoter sequence and
modifying some restriction enzyme sites. The resulting
positive plasmids were designated pSK-Z3 and pSK-Z4,
respectively. Quick-ChangeWMulti Site-Directed Muta-
genesis Kit (Stratagene) was used to introduce two silent
mutations (GCG (Ala)-GCC (Ala), ATC (Ile)-ATA (Ile))into Z3 segment to eliminate Not I (nucleotide position
2980) and one of Bgl II sites (nucleotide position 4233)
(Figure 2), which will be as genetic tags by PCR amplifi-
cation of the parental plasmid pSK-Z3 using Ztu1/Ztu1′
and Ztu2/Ztu2′ primer pairs, respectively. The modified
plasmid named pSK-Z3M, was confirmed by complete
DNA sequencing.
The full-length cDNA clone of O/HN/CHA/93 was
constructed by the following ligations. First, the Spe I-
Xba I fragment (Z12) derived from pMDZ12 was ligated
into pSK-Z3M plasmid which was digested with the same
enzymes. The resulting plasmid was named pSK-Z123.
Then, the Bgl II-Not I fragment (Z4) derived from pSK-
Z4 was cloned into Bgl II- and Not I-digested pSK-Z123
plasmid, leading to the construct pOFS, which containing
the full-length genome of FMDV O/HN/CHA/93 vaccine
strain. The full-length clone was fully sequenced to en-
sure that additional mutations had not been introduced
during cloning. Figure 2 illustrates the strategy for the
construction of the full-length cDNA clone.
Construction of genetically modified FMDV full-length
cDNA clone
For construction of genetically modified FMDV full-
length cDNA clone, overlap PCR fusion were used to
introduce six amino acids substitutions at G-H loop of
VP1 (134 C! S, 137 S!G, 139 A!T, 140 R! S,
142 V!T, 142 S!N). In brief, individual parts were
amplified with ZP1F/ZP3R and ZP2F/ZP4R primer pairs,
respectively, and then these two fragments were fused
by a second round of PCR with primers ZP1F and ZP4R.
Consequently, the desired mutations were in the center
of ZP2R and ZP3F primers. The resulting amplicon was
then digested with BssH II/Xma I and cloned into pSK-
Z3M plasmid, which had been digested with the same
enzymes, leading to the positive clone pSK-Z3MT. The
correct nucleotides were confirmed by complete DNA
sequencing. Then, the plasmid pSK-Z3MT was used as
the backbone for the followings site-directed mutagen-
esis to produce amino acid substitutions (1 C 58 E!D,
1D 43 T!K, and 48 I!V) with HN2729F/HN2729R,
HN3341F/HN3341R, and HN3356F/HN3356R primer
pairs using Quick-ChangeWMulti Site-Directed Mutagen-
esis Kit, respectively. After three rounds of site-directed
mutagenesis, the resulting clone named pSK-Z3MTΔ,
was sequenced to confirm that the expected modifica-
tions had been introduced during amplification. Finally,
the plasmid pSK-Z3MTΔ was digested with Spe I/Bgl II
and cloned into the corresponding region of pOFS
plasmid to produce genetically modified FMDV full-
length cDNA clone pOFSM. The final modified con-
struct was confirmed by complete DNA sequencing.
Table 3 lists the primers used for site-directed mutagen-
esis and overlap PCR fusion.
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The full-length cDNA clone and its derivative were lin-
earized by digestion with Not I and purified using
QIAquick PCR Purification Kit (Qiagen). ConfluentFigure 1 Alignment of amino acid sequences of O/HN/CHA/93 vaccin
consensus are shown. Sequence data of isolates in the present work are obBSR-T7/5 cells (4–6 × 106 in a six-well plate) were sep-
arately transfected with mixtures of 2.5 μg linearized
plasmid DNAs and 15 μl LipofectamineTM 2000 (Invi-
trogen) in a total volume of 1 ml OptiMEM. After 5 he strain and 18 reference viruses. Only sequences different from the
tained from the GenBank.
Table 2 Nucleotide sequence of PCR primers used for the
construction of FMDV O/HN/CHA/93 full-length cDNA
clone















Restriction enzyme sites introduced during clone construction are boxed.
Mutated nucleotides are underlined and in bold.
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tose phosphate broth and 10% FBS was added, and in-
cubation continued for 2 to 3 days at 37°C. The
supernatants were collected when CPE appeared. Each
supernatant was then serially passaged for further
experiments. The total RNA was extracted from pas-
sage 4 supernatant of each rescued virus and analyzed
by RT-PCR followed by sequencing to verify that the
rescued viruses were derived from the cDNA plasmids.
The rescued viruses generated from the full-length plas-
mids pOFS and pOFSM were then designted as r-HN
and rM-HN, respectively.Table 3 Nucleotide sequence of PCR primers used for the con













Mutated nucleotides are underlined and in bold and the codon of the mutation effReplication kinetics of rescued FMDV
To determine the replication kinetics of wild virus and
rescued viruses in more detail, one-step growth was
analyzed. BHK-21 cell monolayers were infected with
wild O/HN/CHA/93 virus as well as two rescued viruses
at a MOI of 0.1 TCID50 per cell. The cells were washed
at 1 h postinfection, and then incubated at 37°C for 4, 8,
12 and 16 h. After incubation, infected cell cultures were
harvested at 4 h intervals and the titer of infectious pro-
geny was determined with TCID50 per milliliter using
Reed–Muench formula.
Stability of the genetically modified virus
Progeny viruses obtained from the full-length plasmids
were serially passaged 10 times in BHK-21 cells. Viral
RNA was extracted from virus stocks collected at pas-
sages 5 and 10. P1 coding region was amplified by RT-
PCR and analyze to evaluate the genetic stability of the
recombinant viruses.
Serological cross-reactivity
Swine serums against O/HN/CHA/93 and rM-HN
viruses were prepared by 28 days post vaccination using
BEI-inactivated 146 S particles. O/Tibet/CHA/99, O/
TAW/TL/97 and O/JX/CHA/2010 isolates were assessed
for their serological relationship (r-value) to the O/HN/
CHA/93 and rM-HN in a two-dimensional neutralisa-
tion test as described elsewhere [31].
Swine immunization and challenge
A total of 110 six-week-old pigs were randomly allocated
to nine groups. Six groups (groups 1–6) consisted of
16 pigs each; whereas three groups of 2 pigs each (groups
7–9) were used as control groups. All animals were sero-
negative for FMDV 3ABC non-structural protein (NSP)









TAAG 3610–3659(C! S,S!G,A! T,
R! S,V! T,S!N)
ACTA 3610–3659(C! S,S!G,A! T,
R! S,V! T,S!N)
3815–3836
ects are indicated in bold. Amino acid changes are shown in brackets.
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HN/CHA/93 and rM-HN to contain 2 μg of BEI-
inactivated, sucrose density gradient purified 146 S FMDV
antigen per 2 ml dose. The inactivated FMDV antigen was
emulsified with Montanide ISA 206 (Seppic, France) oil.
Groups 1, 3, and 5 were vaccinated with 2 ml vaccine con-
taining inactivated O/HN/CHA/93 virus as antigen. Sub-
sequently, groups 2, 4, and 6 were vaccinated with 2 ml
vaccine containing inactivated rM-HN virus as antigen,
whereas groups 7, 8, and 9 were inoculated with minimal
essential medium as non-vaccinated. At 28 days post vac-
cination (dpv), all pigs were challenged intramuscularly
with 105 TCID50/2 ml of different FMDV at the ear-
root-neck area. Briefly, groups 1, 2, and 7 were challenged
with O/Tibet/CHA/99 virus. Groups 3, 4, and 8 were chal-
lenged with O/TAW/TL/97 virus. Groups 5, 6, and 9 were
challenged with O/JX/CHA/2010 virus. Serum samples
were collected from all animals on 0 and 28 dpv for virus
neutralization titer analysis as described previously [32].
The neutralizing antibody titers were calculated as the
log10 of the reciprocal antibody dilution required for 50%
neutralization of 100 TCID50 viruses. The animals were
then observed for the appearance of clinical signs of FMD
daily for 14 days post challenge. Lesions were defined as
described previously [33]. Briefly, localized lesions: vesicles
observed on snout, lips, or one foot during the post-
challenge period; generalized lesions: vesicles observed
on snout, lips, and one or more feet during the post-
challenge period. Two-week post-challenge, all animals
were rebled, and sera were tested for the presence of anti-
bodies to the FMDV non-structural proteins (NSP) 3ABC,
using the commercially available 3ABC-I-ELISA kit.
Samples were considered positive if the cutoff value ≥0.2.
All animal studies were approved by the Review Board of
Lanzhou Veterinary Research Institute, Chinese Academy
of Agricultural Sciences (Permission number: SYXK-
GAN-2004-0005). All animals used in the present studyFigure 2 Strategy used to construct FMDV O/HN/CHA/93 full-length c
restriction enzyme cleavage sites used to assemble the subcloned PCR frag
position in the virus genome). Thick lines and an open box represent the u
polyprotein, respectively. The thin line represents the vector sequence. FMDwere humanely bred to bleed during the experiment and
euthanasia was carried out at the end of the experiment.
Results
Amino acid variation of FMDV isolates of CHY topotype
Deduced amino acid sequence alignments were per-
formed with the data for each isolates of CHY topotype
using SeqMan II. The results indicated that numerous
amino acid replacements occurred in the P1 or VP1 cap-
sid region of the isolates of CHY topotype. These viruses
shared consensus amino acids substitutions at antigenic
site 1 (134 C! S, 137 S!G, 139 A!T, 140 R! S,
141 V!T, 142 S!N), 3 (43 T!K, 48 I!V), and 4
(58 E!D), compared with the O/HN/CHA/93 vaccine
strain. The variations in the antigenic sites may render
the available vaccine ineffective. The differences of
amino acid sequences of FMDV isolates were showed in
Figure 1.
Generation of viruses
FMDV full-length cDNA clone, pOFS, was constructed
in the M-pSK vector from the O/HN/CHA/93 vaccine
strain. A genetically modified full-length clone, pOFSM,
was assembled using overlap PCR fusion and Site-
Directed Mutagenesis, based on the established infec-
tious clone. The modified construct had nine amino
acid differences (VP1 43 T!K, 48 I!V, 134 C! S,
137 S!G, 139 A!T, 140 R! S, 142 V! T, 142 S!N,
VP3 58 E!D ) by sequence analysis, compared with
the pOFS clone. Linearized pOFS and pOFSM plasmids
were transfected into BSR-T7/5 cells to verify whether
cDNA clones were infectious. In day 2 post-transfection,
CPE appeared in both clones, indicating that the two
full-length clones were infectious. Furthermore, some
amino acid substitutions in the vaccine strain genome
did not have an effect on the ability of viral replication
in vitro.DNA clone and genetically modified clone. The location of the
ments (Z1, Z2, Z3 and Z4) are shown (numbered relative to nucleotide
ntranslated regions and the open-reading frame for the viral
V cDNA is under the control of the T7 promoter.
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ments including genetic tags or targeted amino acid sub-
stitutions from viral RNAs of passage 4 to verify that the
two rescued viruses were of recombinant origin. The re-
sult of sequence analysis confirmed that the recovered
viruses were indeed derived from the respective recom-
binant plasmids.
Replication kinetics of rescued FMDV
Single-step growth curves of the rescued viruses and the
wild virus were performed on BHK-21 cells. The results
showed that the rescued viruses had the similar replica-
tion properties to the parental virus on BHK-21 cells
(Figure 3). These results suggest that the substitutions of
amino acid in capsid protein do not affect the ability of
viral replication in vitro.
Stability of the genetically modified FMDV
The recombinant r-HN and rM-HN viruses were serially
passaged 10 times in BHK-21 cells. Consequently, the
amino acid sequence of P1 coding regions of the recom-
binant viruses recovered from passages 5 and 10 were
analyzed. The results revealed that the rescued viruses
remained genetically stable during 10 serial passages
in vitro.
Serological cross-reactivity
The relative homology value (r1) between field isolate
(O/Tibet/CHA/99, O/TAW/TL/97, and O/JX/CHA/
2010) and reference strains (O/HN/CHA/93 and rM-
HN) were determined using two dimensional micro
neutralization tests (Table 4) as previously described
[34]. The results showed that the O/HN/CHA/93Figure 3 Single-step growth curves of wild virus and
recombinant viruses. BHK-21 cells were infected with wild virus
and recombinant viruses at MOI of 0.1 TCID50 per cell. At several
time points, cells were harvested and the titers of the viruses were
determined with TCID50 per milliliter using Reed–Muench formula.reference strains have close antigenic relationship with
O/Tibet/CHA/99 and O/JX/CHA/2010 isolates, but
the O/TAW/TL/97 isolate is antigenically related to
the O/HN/CHA/93 vaccine strain, which indicates that
a more potent vaccine strain needs to be developed
against the variants of the CHY topotype. However, the
rM-HN virus has close antigenic relationship with iso-
lates of three topotypes compared with the wild O/HN/
CHA/93 virus. Therefore, this virus would be used as a
vaccine candidate.
Swine protection experiments
To test the protective efficacy of the inactivated oil-
emulsified vaccines that were prepared from wild O/HN/
CHA/93 strain and the genetically modified virus rM-
HN against the viruses of three topotypes, the present
study designed a swine vaccination and challenge studies.
All pigs immunized with vaccine prepared from rM-HN
were fully protected from clinical disease and viral infec-
tion after challenge with O/Tibet/CHA/99, O/TAW/TL/
97, and O/JX/CHA/2010 viruses. No clinical signs of FMD
were detected in these vaccinated pigs. The pigs vacci-
nated with O/HN/CHA/93 vaccine were completely pro-
tected against O/Tibet/CHA/99 and O/JX/CHA/2010
virus infection. However, 4 of the 16 pigs developed local-
ized lesions after O/TAW/TL/97 virus infection, although
these animals had a delayed appearance of vesicles (4–5
dpc) compared with the control swine. All control ani-
mals in groups 7, 8, and 9 developed generalized FMD
and clinical signs of FMD appeared 2 to 3 days after the
infection of these viruses. All immunized pigs developed a
higher neutralizing antibody against these viruses, except
for the immunized pigs that produced clinical signs of
FMD. The present study indicated that vaccine prepared
from genetically modified FMDV by reverse genetics sig-
nificantly improved protective efficacy to the variant of
the CHY topotype, compared with the O/HN/CHA/93
strain. Tables 5, 6, and 7 present the results of swine pro-
tection experiments. Two weeks post-challenge, animals
were rebled and sera were tested for the presence of anti-
bodies to the nonstructural protein 3ABC. As expected,
antibodies against NSP 3ABC could be detected in un-
vaccinated controls and in the four immunized pigs
that produced clinical signs of FMD after 14 days post-
challenge. Whereas all of the other vaccinated pigs re-
mained NSP seronegative (Tables 5, 6, and 7).
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FMD remains one of the most economically important
diseases of farm animals and is widespread across the
world, especially in Africa, Asia and South America.
Type O FMD is prevalent in China (including Chinese
Taipei, Chinese Hong Kong) and its surrounding coun-
tries [10-13]. Among the epidemic topotypes in these
regions, the viruses in CHY topotype are highly adapted
to pigs [15], which represents the biggest threat on the
Chinese hog industry and the economy. For instance,
in 1997, a devastating and unusual outbreak of FMD
occurred in Taiwan. The outbreak, which was caused by
a CHY topotype virus, rapidly developed into massive
epizootic, resulting in the slaughter of more than 4 mil-
lion pigs and financial losses of over 6 billion U.S. dol-
lars [35,36]. China is the biggest pork producer and
consumer in the world and the pig industry has become
the most important sector in Chinese animal husbandry
[37]. Therefore, control of FMD in swine has become
high priority. Vaccination as a control tool has been
gaining favor as a potentially more effective approach
for controlling the virus, reducing the economic loss to
animal husbandry, and contributing to improved foodTable 5 Responses of pigs to vaccination with O/HN/CHA/93 a





O/HN/CHA/93 101 1.6 - -
102 1.7 - -
103 2.0 - -
104 1.7 - -
105 1.5 - -
106 2.1 - -
107 1.8 - -
108 2.0 - -
109 1.5 - -
110 1.9 - -
111 2.1 - -
112 1.9 - -
113 1.8 - -
114 1.6 - -
115 2.1 - -
116 1.7 - -
Control 117 <1.0 ++ +
118 <1.0 ++ +
a BEI-inactivated virus.
b Day 28 virus neutralization titer (expressed as the log10 of the reciprocal antibody
the means from two repeat tests.
c Scoring of clinical signs: -, no visible lesions, +, localized gross lesions; + +, genera
d Presence of antibodies to the nonstructural protein 3ABC in sera collected 14 day
Samples were considered positive if the cutoff value ≥0.2.security in China. However, currently available FMD
vaccines in China often do not provide complete pro-
tection against some variants arising in the CHY
topotype.
Extensive studies has showed that the G–H loop of
FMDV is the major immunodominant site [38,39], and
it can induce a strong antibody response against the
virus, which is known to play a major role in protection
induced by the current FMDV vaccines [9]. Experimen-
tal peptide or recombinant vaccines [40,41] have been
based mainly on this major antigenic site of FMDV.
In addition, FMDV antigenic variation also occurs
within other antigenic sites, which are implicated in
the full complete immunologic response [9,42]. Based on
these theories, the present study compared amino acid
sequences of the capsid region of O/HN/CHA/93 vaccine
strain and 18 reference isolates of CHY topotype. The
results revealed that consensus amino acid substitutions
occurred at VP1 (43 T!K, 48 I!V 134 C! S, 137 S!G,
139 A!T, 140 R! S, 141 V! T, 142 S!N) and VP3
(58 E!D), which are involved in antigenic site 1, 3,
and 4. Among these substitutions, six were located at the
G-H loop of VP1 and three were located at a positionnd rM-HN vaccines and O/Tibet/CHA/99 challenge





rM-HN 601 2.1 - -
202 1.6 - -
203 1.6 - -
204 2.0 - -
205 1.8 - -
206 2.1 - -
207 1.7 - -
208 1.9 - -
209 1.8 - -
210 2.0 - -
211 1.8 - +
212 2.0 - -
213 1.6 - -
214 2.1 - -
215 1.7 - -
216 2.0 - -
Control 217 <1.0 ++ +
218 <1.0 ++ +
dilution required for 50% neutralization of 100 TCID50 virus) values represent
lized lesions.
s post-challenge, determined by the commercially available 3ABC-I-ELISA kit.
Table 6 Responses of pigs to vaccination with O/HN/CHA/93 and rM-HN vaccines and O/TAW/TL/97 challenge








Lesionsc 3ABCd Lesionsc 3ABCd
O/HN/CHA/93 301 1.8 - - rM-HN 401 2.1 - -
302 1.5 - - 402 1.6 - -
303 1.7 - + 403 1.6 - -
304 1.5 - - 404 1.9 - -
305 1.6 - - 405 1.8 - -
306 1.7 - - 406 2.1 - -
307 0.7 + + 407 1.7 - -
308 1.5 - - 408 1.6 - -
309 1.6 - - 409 1.8 - -
310 0.8 + + 410 2 - -
311 1.8 - - 411 1.8 - -
312 1.0 + + 412 1.7 - -
313 1.5 - - 413 1.6 - -
314 1.6 - - 414 2.1 - -
315 1.7 - - 415 1.7 - -
316 0.8 + + 416 1.6 - -
Control 317 <1.0 ++ + Control 417 <1.0 ++ +
318 <1.0 ++ + 418 <1.0 ++ +
a, b, c, d described as above.
Table 7 Responses of pigs to vaccination with O/HN/CHA/93 and rM-HN vaccines and O/JX/CHA/2010 challenge








Lesionsc 3ABCd Lesionsc 3ABCd
O/HN/CHA/93 501 1.6 - - rM-HN 601 1.9 - -
502 2.3 - - 602 2.1 - -
503 1.7 - - 603 1.6 - -
504 2.0 - - 604 1.7 - +
505 1.9 - - 605 2.0 - -
506 2.0 - - 606 1.8 - -
507 2.2 - - 607 2.0 - -
508 1.7 - + 608 2.1 - -
509 2.1 - - 609 1.7 - -
510 1.8 - - 610 2.0 - -
511 2.1 - - 611 1.7 - -
512 1.9 - - 612 2.0 - -
513 1.6 - - 613 1.9 - -
514 1.8 - - 614 1.8 - -
515 1.6 - - 615 1.7 - -
516 2.2 - - 616 1.7 - -
Control 517 <1.0 ++ + Control 617 <1.0 ++ +
518 <1.0 ++ + 618 <1.0 ++ +
a,b,c,d. described as above.
Li et al. BMC Veterinary Research 2012, 8:57 Page 9 of 12
http://www.biomedcentral.com/1746-6148/8/57
Li et al. BMC Veterinary Research 2012, 8:57 Page 10 of 12
http://www.biomedcentral.com/1746-6148/8/57critical for antigenic sites 3 and 4. Any alteration of crit-
ical residues would confer antigenic specificity to the
FMD viral variants [43-45]. Therefore, we presumed that
the antigenic differences between the variants of CHY
topotype and the current vaccine strain might account
for incomplete protection.
Previous successes in the generation of engineered
avirulent, chimeric, and thermostable FMDV vaccine
candidates [33,46,47] have further provided insight for
designing new vaccine candidate viruses with engineered
modifications by reverse genetics. Therefore, the present
study constructed a full-length infectious clone of O/
HN/CHA/93 vaccine strain and created a genetically
modified construct with amino acid substitutions (1 C
58 E!D, 1D 43 T!K, 48 I!V, 134 C! S, 137 S!G,
139 A!T, 140 R! S, 141 V! T, 142 S!N), based on
vaccine strain framework using a similar strategy. As
expected, a genetically modified virus was obtained from
the modified full-length plasmid. Specifically, amino acid
substitutions in the capsid protein did not affect the
in vitro infectivity properties of the recombinant. Viabil-
ity of the virus indicated that the genome of FMDV O/
HN/CHA/93 can tolerate these amino acid replace-
ments at three antigenic sites. This finding was not sur-
prising, because previous studies have demonstrated that
FMDV can accommodate replacements of G-H loop,
capsid coding region as well as other gene region of
inter-genotypic and intra-genotypic [16,42,48-50]. The
recombinant viruses were genetically stable after 10
serial passages in BHK-21 cells.
As a FMD vaccine candidate, the virus should neces-
sarily grow to high yield in tissue culture for sufficient
antigenic mass to be produced [51]. Therefore, the repli-
cative properties of the recombinant viruses were
assessed by single-step growth curves. The results indi-
cated that the rescued viruses had similar growth prop-
erties to the wild O/HN/CHA/93 virus. In addition, an
ideal vaccine candidate would induce cross protection
against viruses from different antigenic groups within
the subtype. Analysis of antigenic relationships between
the field isolate of the three topotypes and the reference
strains (O/HN/CHA/93 and rM-HN) showed that the
O/HN/CHA/93 reference strains demonstrated close
antigenic relationship with O/Tibet/CHA/99 and O/JX/
CHA/2010 isolates. However, the O/TAW/TL/97 isolate
is antigenically related to the vaccine strain. The rM-HN
virus had close antigenic relationship with isolates of the
three topotypes compared with the O/HN/CHA/93
strain. Thus, this recombinant virus would be used as
vaccine candidate. Comparative efficacy of the inacti-
vated vaccines prepared from the rM-HN and O/HN/
CHA/93 viruses were tested in swine. The results
demonstrated that pigs vaccinated with the O/HN/
CHA/93 vaccine were fully protected from O/Tibet/CHA/99 and O/JX/CHA/2010 virus challenge, but only
75% of the immunized animals were against O/TAW/
TL/97 infection. However, all pigs vaccinated with the
rM-HN vaccine obtained complete protection against O/
Tibet/CHA/99, O/TAW/TL/97, and O/JX/CHA/2010
virus challenge, which may be contribute to the more
antigentic similarities of the genetically modified virus
with the isolate of CHY topotype.
Conclusions
The present study constructed a full-length infectious
cDNA clone of FMDV vaccine strain and created a gen-
etically modified virus with some amino acid substitu-
tions in capsid protein, based on vaccine framework.
Some amino acid substitutions in the FMDV vaccine
strain genome did not have an effect on the ability of
viral replication in vitro. The recombinant viruses had
similar growth properties with the wild O/HN/CHA/93
virus. The vaccine prepared from genetically modified
FMDV significantly improved protective efficacy to the
variants of the CHY topotype, compared with the wild
O/HN/CHA/93 virus. Thus, the full-length cDNA clone
of FMDV can be a useful tool to develop genetically
engineered FMDV vaccine candidates to help control
porcinophilic FMD epidemics in China. Furthermore,
the present study provided further insights for designing
genetically modified FMD vaccine candidate by reverse
genetics, based on the sequence information of arising
mutants during the new FMD outbreak.
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